271 related articles for article (PubMed ID: 28549596)
1. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.
Sleightholm RL; Neilsen BK; Li J; Steele MM; Singh RK; Hollingsworth MA; Oupicky D
Pharmacol Ther; 2017 Nov; 179():158-170. PubMed ID: 28549596
[TBL] [Abstract][Full Text] [Related]
2. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
3. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
4. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
[TBL] [Abstract][Full Text] [Related]
5. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
7. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.
Singh AP; Arora S; Bhardwaj A; Srivastava SK; Kadakia MP; Wang B; Grizzle WE; Owen LB; Singh S
J Biol Chem; 2012 Nov; 287(46):39115-24. PubMed ID: 22995914
[TBL] [Abstract][Full Text] [Related]
8. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis.
Cui K; Zhao W; Wang C; Wang A; Zhang B; Zhou W; Yu J; Sun Z; Li S
J Surg Res; 2011 Nov; 171(1):143-50. PubMed ID: 20462600
[TBL] [Abstract][Full Text] [Related]
9. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis.
Roy I; Zimmerman NP; Mackinnon AC; Tsai S; Evans DB; Dwinell MB
PLoS One; 2014; 9(3):e90400. PubMed ID: 24594697
[TBL] [Abstract][Full Text] [Related]
10. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
11. Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?
Motlak M; Mathews M; Al-Odat OS; Pandey MK
Cytokine; 2024 Jul; 179():156629. PubMed ID: 38704961
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia.
Thomas RM; Kim J; Revelo-Penafiel MP; Angel R; Dawson DW; Lowy AM
Gut; 2008 Nov; 57(11):1555-60. PubMed ID: 18664506
[TBL] [Abstract][Full Text] [Related]
13. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
14. CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.
Mortezaee K
Life Sci; 2020 May; 249():117534. PubMed ID: 32156548
[TBL] [Abstract][Full Text] [Related]
15. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.
Guo F; Wang Y; Liu J; Mok SC; Xue F; Zhang W
Oncogene; 2016 Feb; 35(7):816-26. PubMed ID: 25961926
[TBL] [Abstract][Full Text] [Related]
16. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
17. Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-κB signaling.
Wang J; Wang H; Cai J; Du S; Xin B; Wei W; Zhang T; Shen X
Exp Cell Res; 2018 Apr; 365(1):12-23. PubMed ID: 29453972
[TBL] [Abstract][Full Text] [Related]
18. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.
Tu CC; Arnolds KL; O'Connor CM; Spencer JV
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840
[TBL] [Abstract][Full Text] [Related]
19. The role of CXCL12 in tumor microenvironment.
Meng W; Xue S; Chen Y
Gene; 2018 Jan; 641():105-110. PubMed ID: 29017963
[TBL] [Abstract][Full Text] [Related]
20. CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
Yu X; Shi W; Zhang Y; Wang X; Sun S; Song Z; Liu M; Zeng Q; Cui S; Qu X
Sci Rep; 2017 Feb; 7():42226. PubMed ID: 28176874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
